Table 2.

Complete blood count values for 10 patients with myelodysplastic syndromes with del(5q) at the time of first (prior to treatment with lenalidomide) and second (during treatment with lenalidomide) NGS studies.

pt		Hemoglobin g/dL (or Tx-dep)			Platelets x 10(9)/L			Leukocytes x 10(9)/L
	At Dx	1st NGS	2nd NGS	At Dx	1st NGS	2nd NGS	At Dx	1st NGS	2nd NGS
1	8.9	Tx-dep	Tx-dep	152	174	53	4.2	6.2	3.2
2	9.6	9.6	11.7	142	142	149	5.3	5.3	17.4
3	8.4	8.4	Tx-dep	584	584	215	3.7	3.7	3.6
4		10.1	15.7		232	143		5.6	5.3
5	9.6	9.9	9.6	277	303	269	4	3.9	4.12
6	11.9	9.9	8.4	451	729	101	6	6.6	4.3
7	14.2	14.2	14.5	831	831	629	8.8	5.68	4.29
8	12.2	10.7	7.3	102	90	86	3.1	1.7	2
9	8.3	8.3	Tx-dep	132	132	123	3.5	3.5	3.9
10	10.2	10.2	8	198	395	88	6.3	2.78	1.01

NGS next generation sequencing, Tx-dep red cell transfusion-dependent, Dx diagnosis; 1st NGS, prior to treatment with lenalidomide, 2nd NGS during treatment with lenalidomide, pt patient